Quarterly ResultApr 30, 2026, 04:15 PM
INDV Q1 Revenue $317M, Net Income $89M; $500M Convertible Notes Issued
AI Summary
Indivior Pharmaceuticals, Inc. reported a significant increase in net revenue to $317 million and net income to $89 million for Q1 2026. The company completed its U.S. domestication in January 2026 and issued $500 million in Convertible Senior Notes due 2031, using proceeds to repay $333 million of prior debt, incurring an $18 million loss on extinguishment. The company also faces ongoing dental litigation with approximately 1,900 cases consolidated.
Key Highlights
- Net revenue increased to $317 million in Q1 2026 from $266 million in Q1 2025.
- Net income rose to $89 million in Q1 2026 from $47 million in Q1 2025.
- Basic earnings per share increased to $0.71 in Q1 2026 from $0.38 in Q1 2025.
- Issued $500 million aggregate principal amount of 0.625% Convertible Senior Notes due 2031.
- Repaid $333 million of prior indebtedness, resulting in an $18 million loss on debt extinguishment.
- Operating income for Q1 2026 was $137 million, up from $66 million in Q1 2025.
- SUBLOCADE net revenue in the US was $218 million in Q1 2026, up from $163 million.
- Approximately 1,900 dental litigation cases naming 25,000 plaintiffs are consolidated in MDL.